论文部分内容阅读
目的 探讨自体肿瘤疫苗的作用机制。方法 2 0例进展期肿瘤患者术后第 4周开始以自体肿瘤细胞疫苗行主动免疫治疗。免疫接种共 4次 ,每次间隔 7～ 10d ;接种前 3d及第 4次接种后一周 ,采集外周血 ,分离单个核细胞 ,以流式细胞分析术 /细胞内细胞因子检测法测定CD8+ IFN γ+ ,CD8+ IL 10 + 细胞及CD4+ IFN γ+ ,CD4+ IL 10 + 细胞 ;同时采集血清 ,ELISA法检测血清IFN γ、IL 10水平。结果 自体肿瘤细胞疫苗治疗后 :①血清IFN γ水平升高 [(7.16± 2 .91)ng·L- 1升至 (11.68± 4.86)ng·L- 1,P <0 .0 5] ;而IL 10水平下降 [2 1.0 4± 13 .81)ng·L- 1降至 (13 .41± 5.71)ng·L- 1,P <0 .0 5] ;②CD8+ IFN γ+ 阳性细胞由 (3 .80± 1.45) %升至 (6.94± 2 .63 ) % ;CD4+ IFN γ+ 阳性细胞由 (3 .0 9± 1.52 ) %升至 (5.2 0± 2 .94) % (P <0 .0 5) ;③病人耐受良好。结论 自体瘤细胞疫苗免疫后可改善肿瘤患者细胞介导的抗瘤免疫反应
Objective To explore the mechanism of autologous tumor vaccine. Methods Twenty patients with advanced cancer started active immunotherapy with autologous tumor cell vaccine in the fourth week after operation. Immunization was performed 4 times at intervals of 7-10 days. Peripheral blood was collected three days before inoculation and one week after the fourth inoculation, and mononuclear cells were isolated. The levels of CD8 + IFN γ were determined by flow cytometry / cytokine assay +, CD8 + IL 10 + cells and CD4 + IFN γ +, CD4 + IL 10 + cells. Serum was also collected at the same time. Serum levels of IFN-γ and IL-10 were measured by ELISA. Results After the treatment of self-tumor cell vaccine: ① The serum IFN-γ level increased (7.16 ± 2.91) ng · L-1 to (11.68 ± 4.86) ng · L-1, P <0.05); while The level of IL-10 decreased (2 1.04 ± 13.81) ng · L-1 to (13.41 ± 5.71) ng · L-1, P <0.05). ②CD8 + IFNγ + . The percentage of CD4 + IFNγ + positive cells increased from (3.90 ± 1.52)% to (5.2 ± 2.94)% (P < 5); ③ patient well tolerated. Conclusion The self-tumor cell vaccine can improve cell-mediated anti-tumor immune response in tumor patients